Roche has signed a drug-discovery collaboration with Chinese startup Defand Therapeutics that could be worth close to $1 billion in upfront and milestone payments, Defand said Thursday. Under the agreement, Defand will identify and advance multiple molecular glue candidates against cancer and immune-driven disease targets, with Roche funding the work and holding rights to license resulting programs.

The deal diverges from Roche's recent China transactions. Rather than in-licensing a clinical-stage asset, Roche is underwriting early-stage discovery from a Chinese biotech — a partnership structure that large pharma has historically deployed with Western or Japanese partners.

What is a molecular glue?

Molecular glues are small molecules designed to create a sticky, more effective connection onto problematic proteins in order to destroy them. The modality differs from conventional inhibitors because glues recruit cellular machinery to degrade targets that have historically resisted small-molecule intervention.

What catalyzed the surge in interest?

A clinical readout from Revolution Medicines sharpened investor and pharma attention on the modality. The company's molecular glue Rasonque nearly doubled the survival rate of patients with pancreatic cancer, according to STAT+ reporting. The data positioned an oral therapy as a potential challenger to standard chemotherapy in a tumor type where treatment options have long been limited.

For R&D managers, the implication is portfolio-level. Large pharma groups are increasingly allocating dedicated program lines to degraders rather than treating them as a fringe bet. Roche's deal is one of the first explicit signals that the modality is being sourced through discovery partnerships with Chinese biotechs rather than purely through late-stage licensing.

How is the deal structured?

Defand will run discovery and preclinical development against an undisclosed set of targets agreed with Roche. Roche will fund the work and hold exclusive rights to license each program at a predefined preclinical milestone, after which it will assume full development and commercialization responsibilities. Defand stands to receive an upfront payment plus tiered preclinical, clinical, and regulatory milestones, plus royalties on any approved products.

A person familiar with the agreement said the total could approach $1 billion if all milestones are met, though financial terms were not disclosed publicly.

Neither company named the targets, the number of programs, or the timeline for the first IND filing.

What does the deal signal for R&D budgeting?

The structure reflects three cost-allocation choices that R&D leaders should track. First, pharma is paying upfront to derisk target selection in a modality where attrition has historically been high. Second, the milestone-heavy schedule shifts capital toward back-end clinical and regulatory events rather than near-term discovery budgets. Third, the choice to source discovery from a Chinese partner points to growing cost pressure on Western early-stage research.

For Defand, the deal provides non-dilutive capital to expand a discovery operation. For Roche, it adds capacity at a moment when competitors have already committed to similar programs in the degrader space.

Whether the structure produces marketed drugs will hinge on which targets Defand selects and on Roche's willingness to advance multiple programs in parallel. The first external signal of progress will arrive when either company discloses a target or files an IND — neither of which has been announced.